Logo

BioTrove Inks Screening Deal with Blue Sky

Mar 24, 2006

NEW YORK, March 24 (GenomeWeb News) - BioTrove and Blue Sky will collaborate to create a screening portfolio for challenging drug targets, Biotrove said this week.

 

Under the agreement, BioTrove will use Blue Sky proteins as a component of an assay used by BioTrove's RapidFire platform to screen for biomarkers.

 

The collaboration will focus initially on targets in metabolic disorders and oncology, BioTrove said.

 

Financial details were not provided.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.